New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 19, 2012
10:52 EDTAMRN, GSKFish oil market may be bigger challenge than patents for Amarin, Forbes says
Scientific publications, doctors' commentary, and prescription trends all hint that the U.S. market for prescription fish oil may be shifting dramatically, which could be a bigger problem for Amarin (AMRN) than patent protection for its Vascepa drug, according to Forbes. Use of GlaxoSmithKline's (GSK)Lovaza, an alternative treatment, has declined, the report added. Reference Link
News For AMRN;GSK From The Last 14 Days
Check below for free stories on AMRN;GSK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | all recent news | >>
July 16, 2014
05:38 EDTGSKGSK, Theravance initiate Phase III IMPACT study
GlaxoSmithKline (GSK) and Theravance (THRX) announced the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the 'closed' triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease, or COPD. IMPACT is the first pivotal phase III study in a programme to evaluate a once-daily closed triple combination treatment of an inhaled corticosteroid, or ICS; a long-acting muscarinic antagonist, or LAMA; and a long-acting beta2-adrenergic agonist, or LABA, in patients with COPD. The IMPACT study will enrol approximately 10,000 patients and assess whether the combination of FF, or fluticasone furoate, an ICS, UMEC, or umeclidinium, a LAMA, and VI, or vilanterol, a LABA, all delivered in GSK's Ellipta inhaler, can reduce the annual rate of moderate and severe exacerbations compared with two approved once daily COPD treatments, Relvar/Breo Ellipta, FF/VI, which is an ICS/LABA combination, and Anoro Ellipta, UMEC/VI, which is a LAMA/LABA combination.
<< 1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use